Valion Bio (VBIO) Research & Development (2021 - 2026)
Valion Bio (VBIO) recorded Research & Development of $2.7 million in Q2 2026, up 312.8% from $655,000 a year earlier.
Powered by 
Analysis
Valion Bio (VBIO) Research & Development (2021 - 2026) Analysis & Trends
On a TTM basis, Valion Bio's Research & Development came in at $5.5 million as of Jun 30, 2026, up 215.2% year-over-year; for FY2025, it was $3.13 million, up 138.5% from FY2024.
- Annual Research & Development has a four-year compound annual growth rate of 37.4% (FY2021 to FY2025).
- Across earlier years, Research & Development came in at $1.31 million in FY2024 (-20.7%), $1.66 million in FY2023 (-4.3%), $1.73 million in FY2022 (+97.0%) and $878,000 in FY2021.
- The Q2 2026 figure is the highest quarterly Research & Development in data going back to Q1 2021.
- On a year-over-year basis, Research & Development rose in six of the last seven quarters, with growth averaging 123.8%.
- Peak year-over-year performance for Research & Development in the last five years was growth of 312.8% in Q2 2026, against a decline of 47.8% in Q1 2024 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Valion Bio | 129,792.00 | -19.31 Mn | - | 2.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.70 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 858,000.00 |
| Jun 30, 2025 | 655,000.00 |
| Mar 31, 2025 | 335,000.00 |
| Dec 31, 2024 | 333,000.00 |
| Sep 30, 2024 | 422,000.00 |
| Jun 30, 2024 | 302,000.00 |
| Mar 31, 2024 | 256,000.00 |
| Dec 31, 2023 | 360,000.00 |
| Sep 30, 2023 | 337,000.00 |
| Jun 30, 2023 | 468,000.00 |
| Mar 31, 2023 | 490,000.00 |
| Dec 31, 2022 | 435,000.00 |
| Sep 30, 2022 | 399,000.00 |
| Jun 30, 2022 | 497,000.00 |
| Mar 31, 2022 | 401,000.00 |
| Dec 31, 2021 | 313,000.00 |
| Sep 30, 2021 | 175,000.00 |
| Jun 30, 2021 | 192,000.00 |
API Access
Valion Bio Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=VBIO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "VBIO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=VBIO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();